1 CRISPR/Cas12a-mediated ultrasensitive and on-site monkeypox

2 viral testing

- ³ Furong Zhao^{a, 1}, Pei Wang^{a, b, 1}, Haoxuan Wang^{a, 1}, Sirui Liu^a, Muhammad Sohail^a,
- 4 Xing Zhang^a, Bingzhi Li^{a,*}, He Huang^{a,*}
- ^a School of Food Science and Pharmaceutical Engineering, Nanjing Normal
- 6 University
- ⁷ ^b School of Life Sciences, Nanjing Normal University, Nanjing 210023, China
- 8 ¹ Equal contributions:
- 9 F.Z, P.W, and H.W. contributed equally to this work.
- 10 * Corresponding Author:
- 11 Bingzhi Li (bingzhili@njnu.edu.cn)
- 12 He Huang (huangh@njnu.edu.cn)

14 Abstract

The unexpected transmission of monkeypox virus (MPXV) from Central and 15 16 West Africa to previously non-endemic locations is triggering a global panic. The 17 ultrasensitive, rapid, and specific detection of MPXV is crucial for controlling its spreading, while such technology has rarely been reported. Herein, we proposed an 18 19 MPXV assay combining recombinase-aided amplification (RAA) and CRISPR/Cas12a for the first time. This assay targeted MPXV F3L gene and yielded a 20 21 low detection limit (LOD) of 10^1 copies/ μ L. Deriving from the high specificity nature 22 of RAA and CRISPR/Cas12a, through rational optimizations of probes and conditions, 23 this assay showed high selectivity that could distinguish MPXV from other orthopox 24 viruses and current high-profile viruses. To facilitate on-site screening of potential 25 MPXV carriers, a kit integrating lateral flow strips was developed, enabling naked-eye MPXV detection with a LOD of 10^4 copies/ μ L. Our RAA-Cas12a-MPXV 26 27 assay was able to detect MPXV without the need for sophisticated operation and expensive equipment. We envision that this RAA-Cas12a-MPXV assay can be 28 29 deployed in emerging viral outbreaks for on-site surveillance of MPXV.

Keywords: CRISPR; Cas12a; Monkeypox; Nucleic acid testing; Point-of-care testing

32 Introduction

33	As a member of the genus orthopoxvirus (OPXV) in the family Poxviridae,
34	monkeypox virus (MPXV) is a double-stranded DNA (dsDNA) virus firstly isolated
35	in 1958. ¹⁻³ Monkeypox was not recognized as a zoonotic disease until the first human
36	case discovered in a 9-month-old boy in Zaire (now the Democratic Republic of the
37	Congo) in 1970. ⁴⁻⁶ Animal-to-human transmission of MPXV can occur via humans'
38	close contact with infected animals while human-to-human transmission includes
39	contact with bodily fluids, respiratory droplets, and lesion materials of the infected
40	individual, sexual transmission, and maternal-infant transmission. ^{7, 8} Since the first
41	human case, monkeypox has become predominantly endemic in Central and West
42	Africa, for example, Nigeria experienced a large monkeypox outbreak in 2017, with
43	relevant cases continuously emerging.9-11 It was not until 2003 that the first case
44	occurred in the United States, mainly due to the importation of infected pet prairie
45	dogs from Ghana. Since 2018, monkeypox has also been reported in tourists from
46	Nigeria to other non-endemic countries, involving Israel, ¹² the United Kingdom, ^{13, 14}
47	Singapore, ¹⁵ the United States of America, ^{16, 17} and others. ¹⁸ Disturbingly, the World
48	Health Organization (WHO) has collected a total of 71,237 laboratory-confirmed
49	cases and 1,097 probable cases from 107 infected member countries since 1 January
50	2022, and declared this outbreak a public health emergency of international concern. ¹⁹
51	It has become a new reality that human monkeypox is no longer a rare zoonotic
52	disease, which deserves more public health attention. ²⁰ Thus, the detection of
53	monkeypox matters even more in the current post-COVID, more vigilant world. ²¹

54	Currently, the MPXV testing relies on methods including polymerase chain
55	reaction (PCR), ²²⁻²⁴ enzyme-linked immunosorbent assay (ELISA), ^{25, 26}
56	loop-mediated isothermal amplification (LAMP), ²⁷ and microarray. ^{28, 29} PCR,
57	recognized as the gold standard for the diagnosis of various diseases including
58	monkeypox, displays high accuracy and sensitivity, yet its application in low-resource
59	areas is limited due to its requirements for expensive equipment and skilled
60	operators. ³⁰ ELISA may fail in providing MPXV-specific analysis for the
61	serologically cross-reactive characteristic of OPXV and lead to false positive results
62	for recent or remote vaccination. ³¹ LAMP is free from precise thermo-cycling, but it
63	suffers from complicated primer design, false positives, and poor quantitative
64	performance. Besides, the microarray method has been developed for the detection
65	and discrimination of OPXV species; however, its practicality and accessibility is
66	limited deriving from high cost and long detection time. ³² Therefore, low-cost,
67	ultrasensitive, and rapid methods that can facilitate on-site and facile MPXV detection
68	have remained elusive.

69 CRISPR/Cas (clustered regularly interspaced short palindromic repeats and 70 CRISPR-associated protein) discovered in the adaptive immune system of 71 prokaryotes, was initially proposed as a revolutionary gene editing technology and 72 later expanded to the fields of molecular diagnosis and biosensing.^{33, 34} 73 CRISPR/Cas12a system that integrates biorecognition (Cas12a crRNA binding to the 74 target) with signal transduction (activated Cas12a indiscriminately cleaving any 75 surrounding single-stranded DNA reporters) has participated in the detection of

76	various viruses, including severe acute respiratory syndrome coronavirus 2
77	(SARS-CoV-2), ³⁵ African swine fever virus (ASFV), ³⁶ human immunodeficiency
78	virus (HIV),37 displaying obvious advantages of mild conditions, operational
79	simplicity, great sensitivity, and potent signal amplification. ^{38, 39} Currently, the
80	CRISPR/Cas12a-based MPXV assay has not been systematically reported. According
81	to the best of our acknowledge, there is only one short letter discussed the possibility
82	of implementing CRISPR technology in MPXV detection, while details on
83	pre-amplification, probe screening, analytical performance, and point-of-care testing
84	(POCT) have not been included. ⁴⁰

85 Herein, we proposed an ultrasensitive and rapid MPXV assay that integrates recombinase-aided amplification (RAA) with CRISPR/Cas12a 86 (the 87 RAA-Cas12a-MPXV assay) for the first time. After RAA pre-amplification of DNA 88 templates (containing MPXV F3L gene), CRISPR/Cas12a-based amplicon recognition, and rapid cleavage of reporters, ultrasensitive detection of MPXV down 89 to 10^1 copies/ μ L via fluorescence readout was accomplished, which is 1000-fold more 90 sensitive than PCR. For MPXV POCT, we chose lateral flow strip technology as the 91 reliable interpretation of the assay and achieved the detection limit of 10^4 copies/µL. 92 Our RAA-Cas12a-MPXV assay has the potential to detect MPXV with excellent 93 94 sensitivity, and selectivity with the aid of basic heaters, providing a rapid, convenient, visual method for on-site screening in low-resource regions. 95

97 **Results and Discussion**

98 Principle and verification of RAA-Cas12a-MPXV Assay

99 The principle of our RAA-Cas12a-MPXV assay is illustrated in Scheme 1. It 100 consists of three steps: RAA amplification, CRISPR/Cas12a cleavage, and signal 101 output. In the first step, RAA selecting the DNA template, the conserved region of MPXV-specific F3L gene, $^{41-43}$ as the target sequence, produces numerous amplicons 102 103 enhanced the sensitivity of the assay. In the second step, crRNA-specific recognition 104 and binding of amplicons activate the *trans*-cleavage activity of Cas12a, resulting in a 105 large number of ssDNA reporters cleaved. Depending on different reporters, the third 106 step presents two modes of signal output, fluorescence assay for FQ reporters 107 (modified with 6-FAM at the 5' end and BHQ1 at the 3' end) and lateral flow strip 108 assay for FB reporters (modified with 6-FAM at the 5' end and biotin at the 3' end), 109 improving the suitability and usability of our RAA-Cas12a-MPXV assay. The 110 departure of fluorophores of FQ reporters from quenchers enables fluorescence assay 111 using a fluorescence reader. In lateral flow strip assay, biotin of FB reporters is 112 captured by streptavidin at the first line on the strip (control), while the 113 FAM/anti-FAM antibody/AuNP complex migrates toward the second line (test) and 114 bind to anti-FAM. The result is visible within 5 min after sample addition at room 115 temperature, and the appearance of red color at the test band is considered positive.





Scheme 1. The principle of RAA-Cas12a-MPXV assay proposed in this research.
RAA for DNA template amplification; CRISPR/Cas12a system for reporter cleavage;
fluorescence assay and lateral flow strip assay for detection signal output.

To assess the feasibility of our RAA-Cas12a-MPXV assay, we compared 120 121 fluorescence results with or without DNA templates, and RAA product. As shown in 122 Figure 1A, the control group without DNA templates brought no significant 123 fluorescence change (NTC, blue line), indicating that no RAA amplicon was 124 generated for recognition by subsequent CRISPR/Cas12a in the absence of DNA 125 templates. The blank control without RAA product also showed no fluorescent signal, 126 demonstrating that CRISPR/Cas12a system does not cleave reporters without 127 amplicons (NRP, black line). Accordingly, we excluded the possibility of false 128 positive results due to contamination and non-specific amplification during RAA, as 129 well as non-specific cleavage of reporters during CRISPR/Cas12a. In contrast, in the 130 presence of DNA templates, RAA replicated numerous amplicons for crRNA recognition and Cas12a activation, resulting in an intense fluorescence signal (red 131

- 132 line). The results obtained by the fluorescence reader were consistent with the
- 133 fluorescence spectroscopy (Figure 1B). Moreover, the fluorescence signal could be
- 134 observed by the naked eyes under ultraviolet (UV) light (Figure 1B, inset).



135

Figure 1. Verification of RAA-Cas12a-MPXV testing strategy. (a) Fluorescence spectra of feasibility verification. (b) Fluorescence intensity of feasibility verification. The inset was photographed by a smartphone under UV light. RAA was carried out under 42 °C for 30 min using F2 and R2, then 1 μ L RAA product was added to 20 μ L CRISPR/Cas12a reaction (50 nM Cas12a, 50 nM CrRNA, 1 μ M FQ reporter, 1 × Cas Buffer). NRP, no RAA product; NTC, no template control; P, positive.

142 Design and screening of RAA primers and Cas12a crRNA

143 RAA primers are the main factors affecting RAA amplification efficiency. To 144 obtain higher sensitivity and selectivity, three pairs of primers binding at different 145 sites of the MPXV-specific *F3L* gene were designed (Figure 2a, Table S1). Agarose 146 gel electrophoresis (AGE) and the RAA-Cas12a-MPXV fluorescence assay were 147 performed to screen the optimal primers for further experiments. The result of AGE 148 suggested that amongst the three pairs of RAA primers, only the third pair (F2+R2)

- achieved the brightest specific amplification band while having no non-specific
 amplification band (Figure 2b). The fluorescence assay further confirmed F2 and R2
 as the most efficient primers, with the lowest fluorescence in NTC and the highest
- 152 fluorescence in P (Figure 2c).



Figure 2. Screening optimal primers for RAA. (a) The binding sites of designed primers on the DNA template. (b) AGE of RAA product. M, DNA marker; lane NTC1 and P1, RAA products using F1.1 and R1; lane NTC2 and P2, RAA products using F1.2 and R1; lane NTC3 and P3, RAA products using F2 and R2. (c) Fluorescence intensity of RAA-CRISPR/Cas12a assay. NTC, no template control; P, positive.

159 Cas12a crRNA plays a central role in amplicon recognition and Cas12a 160 activation, thus, to obtain the optimized crRNA that can potently activate Cas12a, we 161 designed three crRNAs with the same length, while targeting to different sites on the 162 RAA amplicon (Figure 3a). All of the crRNAs we designed activated Cas12a which

163	subsequently cis-cleaved amplicons (no bands in the insert of Figure 3b) and
164	trans-cleaved FQ reporters (rising fluorescence in Figure 3b), while crRNA2 was the
165	best candidate for its highest fluorescence intensity. With crRNA2-activating
166	CRISPR/Cas12a, we observed a considerable fluorescence difference between the
167	negative group and the positive group (Figure 3c). Consequently, we selected crRNA2
168	for the following study.



170 Figure 3. Screening an optimal crRNA for CRISPR/Cas12a. (a) The binding sites of 171 designed crRNAs on the DNA template (Green, crRNA binding sites; purple, PAM motifs). (b) Fluorescence intensity of CRISPR/Cas12a assay using different crRNAs. 172 173 NC, no crRNA. The inset was an agarose gel image corresponding to different groups. 174 Lane NC, CRISPR/Cas12a reaction products with no crRNA; lane crRNA1, CRISPR/Cas12a reaction products using crRNA1; lane crRNA2, CRISPR/Cas12a 175 176 reaction products using crRNA2; lane crRNA3, CRISPR/Cas12a reaction products 177 using crRNA3. (c) Fluorescence intensity of CRISPR/Cas12a assay using the

178 optimum crRNA2. Negative, without templates; positive, with templates.

179 **Optimization of the assay conditions**

180	To obtain optimal analytical performance of our RAA-Cas12a-MPXV assay,
181	several critical experimental conditions during RAA amplification and the
182	CRISPR/Cas12a system were optimized. We first optimized the temperature and
183	reaction time of RAA based on the optimal primers (F2 and R2). The band of 30-min
184	RAA was significantly brighter than that of other amplification times (Figure 4a), and
185	the fluorescence result reconfirmed 30 min as the ideal RAA reaction time (Figure S1).
186	Likewise, we chose 42 \square as the optimal temperature for RAA by combining the
187	results of electrophoresis and fluorescence assay (Figure 4b, Figure S1).
188	After the determination of RAA amplification conditions (42 \Box , 30 min), we
189	further optimized the CRISPR/Cas12a system with crRNA2. We first investigated the
190	cleavage ability of Cas12a at different reaction times. The fluorescence intensity
191	spiked rapidly from the onset of the reaction to 40 min, and the cleavage efficiency
192	reached its maximum at 40 min, after which the fluorescence slowly increased (Figure
193	4c), thus, we chose 40 min as the best CRISPR reaction time. Furthermore, we

194 explored the effects of Cas12a:crRNA on the ultimate fluorescence intensity and

195 found that 1:1 was the optimal ratio (Figure 4d).



Figure 4. Optimization of the assay conditions. (a) The agarose gel image of RAA 197 198 amplification products under different reaction times (15 min, 20 min, 25 min, 30 min, 199 35 min). (b) The agarose gel image of RAA amplification products under different 200 temperatures (42 \Box , 39 \Box , 37 \Box , 35 \Box , 32 \Box). NTC, no template control. (c) 201 Fluorescence intensity of CRISPR/Cas12a assay under different reaction times (10 202 min, 20 min, 30 min, 40 min, 50 min, 60 min, 70 min). Cleavage efficiency = 203 fluorescence intensity/CRISPR time. (d) Fluorescence intensity of CRISPR/Cas12a 204 assay using different ratios of Cas12a and crRNA (10:1, 5:1, 1:1, 1:5, 1:10). NC, no 205 crRNA.

206 Performances of the proposed RAA-Cas12a-MPXV fluorescence assay

As shown in Figure 5a, our proposed RAA-Cas12a-MPXV fluorescence assay has the merits of easy operation and rapid testing. To evaluate the sensitivity of the

209	fluorescence assay, DNA templates at serial dilution concentrations in the range of 10°
210	to 10^{10} copies/µL were subjected to RAA amplification, and then a 1 µL amplification
211	product was taken for the CRISPR/Cas12a reaction. The resulting fluorescence
212	intensity in Figure 5a exhibited that compared to the control group without the DNA
213	template and RAA product, the difference initiated in the group of 10^1 copies/ μ L, and
214	gradually widened in the following groups, hence the limit of detection (LOD) of the
215	RAA-Cas12a-MPXV fluorescence assay was 10^1 copies/µL. Additionally, we
216	achieved the LOD of 10^2 copies/ μ L via naked-eye observation under UV light (Figure
217	5b, insert). We also evaluated the sensitivity of the PCR-Cas12a-MPXV fluorescence
218	assay (detailed in Supporting Information). In comparison with the
219	PCR-Cas12a-MPXV fluorescence assay, the LOD of which was 10^4 copies/ μ L (Figure
220	S2), the RAA-Cas12a-MPXV fluorescence assay we established achieved 1000-fold
221	lower LOD, performing outstanding sensitivity. The higher sensitivity of RAA-based
222	assay is ascribed to the higher amplification efficiency of RAA and the better
223	compatibility of RAA to CRISPR. ⁴⁴⁻⁴⁶

The selectivity of our RAA-Cas12a-MPXV fluorescence assay was next assessed by comparing the fluorescence intensity produced by MPXV with that produced by other viruses: cowpox virus (CPXV), variola virus (VARV), ASFV, and *Toxoplasma Gondii* virus (TOXV), SARS-CoV-2. Both fluorescence values and naked-eye observation demonstrated that only the MPXV group induced enhanced fluorescence while other orthopox viruses (CPXV and VARV), and current high-profile viruses (ASFV, TOXV, SARS-CoV-2) showed no fluorescence changes (Figure 5c). These

- 231 results confirmed the superior selectivity of our strategy toward MPXV, which is
- 232 derived from the outstanding specificity of RAA amplification and Cas12a
- 233 recognition.⁴⁷⁻⁴⁹



Figure 5. Performances of the RAA-Cas12a-MPXV fluorescence assay. (a) Flowchart 235 236 of the fluorescence assay. (b) Fluorescence intensity responding to a serial 10-fold dilution (10^{10-0} copies/ μ L) of DNA templates in the sensitivity evaluation. The inset 237 238 was photographed by a smartphone under UV light. Copy numbers and serial dilution values that are significantly different from each other are labeled with different 239 240 lowercase letters above the error bars (p < 0.05). (c) Fluorescence intensity responding to MPXV, CPXV, VARV, ASFV, TOXV, and SARA-CoV-2 in the 241 selectivity evaluation. The inset was photographed by a smartphone under UV light. 242 243 NRP, no RAA product; NTC, no template control.

244 RAA-Cas12a-MPXV Lateral Flow Strip Assay for Point-of-Care Testing

245 To enable POCT, we designed the FB reporter as a substitute for the FQ reporter 246 of the fluorescence assay and established the RAA-Cas12a-MPXV lateral flow strip 247 assay (Figure 6a). Upon the addition of the reaction solution containing both intact FB 248 reporters and cracked FAMs and biotins at the sample pad, the anti-FAM 249 antibody/AuNP complexes quickly bound to the isolated FAMs as well as the intact 250 FB reporters as the sample migrated forward. Subsequently, the streptavidin, which 251 was immobilized at the control band, captured the cracked biotins and the FB 252 reporter/anti-FAM antibody/AuNP complexes, so that the control band appeared red 253 owing to the aggregation of AuNPs. The rest isolated FAM/anti-FAM antibody/AuNP 254 complexes migrated toward the test band and were captured by the FAM antibodies, 255 appearing red. Once there were enough amplicons to activate Cas12a to cleave all FB 256 reporters at maximum capacity, the color change would only appear at the test band as 257 a result. In brief, the color change appearing at the test band only or both the control 258 band and the test band indicated a positive result. In the negative group, the absence 259 of the DNA templates led to no amplicons for Cas12a activation and reporters 260 cleavage, consequently, the red color appeared only at the control band.

In the sensitivity assessment, with the increasing number of DNA templates, amplicons for crRNA recognition and Cas12a activation incrementally grew via RAA, eventually leading to a growing number of FB reporters being cleaved into FAM and biotin, allowing the result that the color became darker at the test band and became lighter at the control band presented on the lateral flow strips. Through naked-eye observation, our RAA-Cas12a-MPXV lateral flow strip assay achieved the LOD of

267 10^4 copies/µL (Figure 6b). Besides, this lateral flow strip assay showed great

selectivity, as demonstrated by the cross-reactivity test with other orthopox viruses

and current high-profile viruses (Figure 6c).



Figure 6. Performances of the RAA-Cas12a-MPXV lateral flow strip assay. (a) Flowchart of the lateral flow strip assay. (b) Lateral flow strip results responding to a serial 10-fold dilution $(10^{10-0} \text{ copies/}\mu\text{L})$ of DNA templates in the sensitivity evaluation. (c) Lateral flow strip results responding to MPXV, CPXV, VARV, ASFV, TOXV, and SARA-CoV-2 in the selectivity evaluation. NTC, no template control.

277 Conclusions

278 In this work, we established an RAA-Cas12a-MPXV assay for ultrasensitive, facile, and rapid detection of MPXV by integrating RAA amplification with 279 280 CRISPR/Cas12a system and outputting the detection signal in the form of 281 fluorescence or lateral flow strip. Compared to current methods reported for detecting 282 MPXV, our RAA-Cas12a-MPXV assay possessed its notable strengths: (1) our assay 283 was carried out at a gentle temperature throughout, getting rid of the restraints of 284 thermal cycling processes and expensive instruments; (2) compared to the conventional PCR with the LOD of 10^4 copies/ μ L, our assay exhibited a significantly 285 improved detection limit of 10^1 copies/ μ L in the fluorescence assay, 1000-fold more 286 287 sensitive than PCR. Meanwhile, visualized detection was realized with the LOD of 288 10^2 copies/µL via UV light, and 10^4 copies/µL via lateral flow strip; (3) combining the 289 lateral flow strip enabled us to perform on-site detection via naked eyes within 5 min at room temperature with no need for any lab equipment, revealing the POCT 290 291 potential for screening MPXV in low-equipment scenario. Overall, the 292 RAA-Cas12a-MPXV assay is a promising method for MPXV detection with 293 outstanding sensitivity, selectivity, and portability.

294

295 **Experimental section**

296 Materials and Reagents

297 The oligonucleotides used in this study were synthesized and purified by Sangon Biotech (Shanghai, China) and listed in Table S1. The monkeypox virus F3L plasmid 298 299 was purchased from Sangon Biotech. The RAA nucleic acid amplification kit 300 (S001ZC) was purchased from ZC Bioscience (Hangzhou, China). The $2 \times Taq$ 301 Master Mix (P111) for PCR and the fastpure gel DNA extraction mini kit (DC301) 302 were provided from Vazyme Biotech (Nanjing, China). The Cas12a nuclease was 303 expressed and purified by our laboratory, details were provided in the supporting information. Reagents in the 10 × Cas Buffer (500 mM NaCl, 100 mM Tris-HCl, 100 304 305 mM MgCl₂, 1 mg/mL BSA, pH 7.9) were purchased from Aladdin (Shanghai, China). 306 The lateral flow strip was purchased from IVD Biotech Service Center (Shanghai, 307 China).

308 **Primers and crRNAs Design**

309 The MPXV F3L gene sequence in this study was derived from German strain 310 MPXV-BY-IMB25241 (GenBank: ON568298) in May 2022 and American strain 311 MPXV-USA-2022-MA001 (GenBank: ON563414) during the same period, the 312 difference of which from Zaire strain Zaire-96-1-16 (NCBI Gene ID: 928998) was a 313 partial site mutation. Referring to the previously reported PCR primers for Zaire strains with some changes,⁵⁰ we designed three pairs of RAA primers and screened 314 315 out the best primers in the follow-up. Cas12a crRNA consisted of a repeat sequence and a amplicon -specific sequence. We designed three 19-nt crRNAs without the PAM 316

motif (TTTN), while the PAM motif appeared at the 5' end of the non-complementary

318 DNA sequence being targeted.

319 Plasmid Construction and Amplification

320 The gene sequences of CPXV, VARV, ASFV, and Toxoplasma Gondii virus 321 (TOXV) were retrieved from GenBank under accession number X75158, AY552594, 322 MN809121 and AF146527, then cloned into PUC57 vectors (Sangon, China) to create the recombinant plasmids. After transformation into E. coli DH5 α and expansion 323 324 overnight, the recombinant plasmids were extracted using AxyPrep plasmid DNA 325 mini kit (AP-MN-P-50) purchased from Axygen Biotech (Hangzhou, China). The 326 concentrations of extracted plasmids were determined with NanoDrop 2000 (Thermo 327 Fisher, United States).

328 Recombinase-Aided Amplification Reaction

329 RAA reaction was performed with the RAA nucleic acid amplification kit, 330 following the manufacturer's instructions. Explicitly, the reaction powder was 331 dissolved with a mixture containing 5 μ L A Buffer (provided in the kit), 0.4 μ L each 332 of 10 μ M forward primer and reverse primer, and 2.7 μ L ddH₂O. Then, 1 μ L DNA 333 template and 0.5µL B Buffer (provided in the kit) were added into the reaction tube 334 and mixed gently, followed by incubation at 42 °C for 30 min. The DNA template was 335 replaced by ddH₂O in no template control (NTC) reaction. RAA products were 336 verified by 3 % AGE after purification by the fastpure gel DNA extraction mini kit. 337 The optimum primers for RAA were screened under the observation of the brightness of the specific bands and the absence of non-specific bands after electrophoresis. 338

339 RAA-Cas12a-MPXV Fluorescence Assay

340	The RAA-Cas12a-MPXV fluorescence assay was performed in a 20 μL system
341	containing 1 \times Cas Buffer, 50 nM crRNA, 50 nM Cas12a, 1 μM FQ reporter, and 1 μL
342	RAA product. Cas12a and crRNA were pre-conjugated in Cas Buffer at 37 °C for 10
343	min to facilitate cleavage performance of Cas12a. After the addition of FQ and RAA
344	product, the CRISPR reaction was incubated at 37 °C for 40 min and observed under
345	the FAM channel of the BioTek Synergy H1M microplate reader (Bio-Tek, United
346	States). In no RAA product (NRP) reaction, ddH ₂ O was in place of the RAA product.

347 RAA-Cas12a-MPXV Lateral Flow Strip Assay

The reaction system of the RAA-Cas12a-MPXV lateral flow strip assay was similar to the fluorescence assay above, except for the replacement of the FQ with the FB reporter. After incubation at 37 °C for 40 min, sterile ddH₂O was added to make up the reaction system to 50 μ L for the insertion of the lateral flow strip. The result was visualized after 5 min incubation at room temperature. The color appeared only at the control band, indicating a negative result, and the color appeared at the test band or both bands, indicating a positive result.

355 Statistical Analysis

Software OriginPro 2021 (OriginLab, Northampton, MA) was used for statistical analyses and graphs. Data were shown as the average \pm standard deviation (n = 3). Error bars represent the standard deviation from three independent experiments.

359

360 Acknowledgments

361	This work was supported by grants from the Natural Science Foundation of
362	Jiangsu Province (No. BK20200718 to B.Li), the Natural Science Foundation of the
363	Jiangsu Higher Education Institutions of China (20KJB350010 to B.Li), Jiangsu
364	Innovation and Entrepreneurship Doctoral Program to X.Zhang, and Jiangsu
365	Specially-Appointed Professor Project to X.Zhang.

366 Conflict of Interest Disclosure

367 The authors declare no competing financial interest.

369 **References**

- 370 (1) Xiang, Y.; White, A. Monkeypox virus emerges from the shadow of its more
- 371 infamous cousin: family biology matters. Emerg Microbes Infec 2022, 11 (1),

372 1768-1777.

- 373 (2) Bunge, E. M.; Hoet, B.; Chen, L.; Lienert, F.; Weidenthaler, H.; Baer, L. R.;
- 374 Steffen, R. The changing epidemiology of human monkeypox-A potential threat? A
- 375 systematic review. *PLoS Negl Trop Dis* **2022**, *16* (2), e0010141.
- 376 (3) Organization, W. H. Monkeypox. 2022.
- 377 <u>https://www.who.int/news-room/fact-sheets/detail/monkeypox.</u>
- 378 (4) Lai, C. C.; Hsu, C. K.; Yen, M. Y.; Lee, P. I.; Ko, W. C.; Hsueh, P. R. Monkeypox:
- 379 An emerging global threat during the COVID-19 pandemic. J Microbiol Immunol
- 380 *Infect* **2022**. DOI: 10.1016/j.jmii.2022.07.004.
- (5) McFadden, G. Poxvirus tropism. *Nat Rev Microbiol* **2005**, *3* (3), 201-213.
- (6) Plowright, R. K.; Parrish, C. R.; McCallum, H.; Hudson, P. J.; Ko, A. I.; Graham,
- A. L.; Lloyd-Smith, J. O. Pathways to zoonotic spillover. Nat Rev Microbiol 2017, 15
- 384 (8), 502-510.
- 385 (7) Murphy, H.; Ly, H. The potential risks posed by inter- and intraspecies
- transmissions of monkeypox virus. *Virulence* **2022**, *13* (1), 1681-1683.
- 387 (8) Di Giulio, D. B.; Eckburg, P. B. Human monkeypox: an emerging zoonosis.
- 388 *Lancet Infect Dis* **2004**, *4* (1), 15-25.
- 389 (9) Reed, K. D.; Melski, J. W.; Graham, M. B.; Regnery, R. L.; Sotir, M. J.; Wegner,
- 390 M. V.; Kazmierczak, J. J.; Stratman, E. J.; Li, Y.; Fairley, J. A.; et al. The detection of

- 391 monkeypox in humans in the Western Hemisphere. N Engl J Med 2004, 350 (4),
- **392 342-350**.
- (10) Rimoin, A. W.; Mulembakani, P. M.; Johnston, S. C.; Lloyd Smith, J. O.; Kisalu,
- N. K.; Kinkela, T. L.; Blumberg, S.; Thomassen, H. A.; Pike, B. L.; Fair, J. N.; et al.
- 395 Major increase in human monkeypox incidence 30 years after smallpox vaccination
- campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A
- **2010**, *107* (37), 16262-16267.
- 398 (11) Durski, K. N.; McCollum, A. M.; Nakazawa, Y.; Petersen, B. W.; Reynolds, M.
- 399 G.; Briand, S.; Djingarey, M. H.; Olson, V.; Damon, I. K.; Khalakdina, A. Emergence
- 400 of Monkeypox West and Central Africa, 1970-2017. MMWR Morb Mortal Wkly Rep
- **401 2018**, *67* (10), 306-310.
- 402 (12) Erez, N.; Achdout, H.; Milrot, E.; Schwartz, Y.; Wiener-Well, Y.; Paran, N.; Politi,
- 403 B.; Tamir, H.; Israely, T.; Weiss, S.; et al. Diagnosis of Imported Monkeypox, Israel,
- 404 2018. *Emerg Infect Dis* **2019**, *25* (5), 980-983.
- 405 (13) Hobson, G.; Adamson, J.; Adler, H.; Firth, R.; Gould, S.; Houlihan, C.; Johnson,
- 406 C.; Porter, D.; Rampling, T.; Ratcliffe, L.; et al. Family cluster of three cases of
- 407 monkeypox imported from Nigeria to the United Kingdom, May 2021. Euro Surveill
- **408 2021**, *26* (32), 2100745.
- 409 (14) Vaughan, A.; Aarons, E.; Astbury, J.; Balasegaram, S.; Beadsworth, M.; Beck, C.
- 410 R.; Chand, M.; O'Connor, C.; Dunning, J.; Ghebrehewet, S.; et al. Two cases of
- 411 monkeypox imported to the United Kingdom, September 2018. Euro Surveill 2018,
- 412 23 (38), 2-6.

- 413 (15) Ng, O. T.; Lee, V.; Marimuthu, K.; Vasoo, S.; Chan, G. H.; Lin, R. T. P.; Leo, Y. S.
- 414 A case of imported Monkeypox in Singapore. *Lancet Infect Dis* 2019, *19* (11),
 415 1166-1166.
- 416 (16) Rao, A. K.; Schulte, J.; Chen, T. H.; Hughes, C. M.; Davidson, W.; Neff, J. M.;
- 417 Markarian, M.; Delea, K. C.; Wada, S.; Liddell, A.; et al. Monkeypox in a Traveler
- 418 Returning from Nigeria Dallas, Texas, July 2021. Mmwr-Morbid Mortal W 2022, 71
- 419 (14), 509-516.
- 420 (17) Costello, V.; Sowash, M.; Gaur, A.; Cardis, M.; Pasieka, H.; Wortmann, G.;
- 421 Ramdeen, S. Imported Monkeypox from International Traveler, Maryland, USA, 2021
- 422 (Response). *Emerg Infect Dis* **2022**, *28* (8), 1738-1738.
- 423 (18) Yinka-Ogunleye, A.; Aruna, O.; Dalhat, M.; Ogoina, D.; McCollum, A.; Disu, Y.;
- 424 Mamadu, I.; Akinpelu, A.; Ahmad, A.; Burga, J.; et al. Outbreak of human
- 425 monkeypox in Nigeria in 2017-18: a clinical and epidemiological report. Lancet Infect
- 426 *Dis* **2019**, *19* (8), 872-879.
- 427 (19) Organization, W. H. 2022 Monkeypox Outbreak: Global Trends. 2022.
 428 https://worldhealthorg.shinyapps.io/mpx_global/.
- 429 (20) Huhn, G. D.; Bauer, A. M.; Yorita, K.; Graham, M. B.; Sejvar, J.; Likos, A.;
- 430 Damon, I. K.; Reynolds, M. G.; Kuehnert, M. J. Clinical characteristics of human
- 431 monkeypox, and risk factors for severe disease. *Clin Infect Dis* 2005, *41* (12),
 432 1742-1751.
- 433 (21) Dzobo, M.; Gwinji, P. T.; Murewanhema, G.; Musuka, G.; Dzinamarira, T.
- 434 Stigma and public health responses: Lessons learnt from the COVID-19 pandemic to

435	inform the recent mon	keypox outbreak.	Public Health	Pract (Oxf	f) 2022 , <i>4</i> , 100315.
-----	-----------------------	------------------	---------------	------------	-------------------------------------

- 436 (22) Li, Y.; Zhao, H.; Wilkins, K.; Hughes, C.; Damon, I. K. Real-time PCR assays for
- the specific detection of monkeypox virus West African and Congo Basin strain DNA.
- 438 *J Virol Methods* **2010**, *169* (1), 223-227.
- 439 (23) Chelsky, Z. L.; Dittmann, D.; Blanke, T.; Chang, M.; Vormittag-Nocito, E.;
- 440 Jennings, L. J. Validation Study of a Direct Real-Time PCR Protocol for Detection of
- 441 Monkeypox Virus. *J Mol Diagn* **2022**. DOI: 10.1016/j.jmoldx.2022.09.001.
- 442 (24) Huggett, J. F.; French, D.; O'Sullivan, D. M.; Moran-Gilad, J.; Zumla, A.
- 443 Monkeypox: another test for PCR. *Euro Surveill* **2022**, *27* (32).
- 444 (25) Karem, K. L.; Reynolds, M.; Braden, Z.; Lou, G.; Bernard, N.; Patton, J.; Damon,
- 445 I. K. characterization of acute-phase humoral immunity to monkeypox: use of
- 446 immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox
- 447 infection during the 2003 North American outbreak. *Clin Diagn Lab Immunol* **2005**,
- 448 *12* (7), 867-872.
- 449 (26) Dubois, M. E.; Hammarlund, E.; Slifka, M. K. Optimization of peptide-based
- 450 ELISA for serological diagnostics: a retrospective study of human monkeypox
- 451 infection. *Vector Borne Zoonotic Dis* **2012**, *12* (5), 400-409.
- 452 (27) Iizuka, I.; Saijo, M.; Shiota, T.; Ami, Y.; Suzaki, Y.; Nagata, N.; Hasegawa, H.;
- 453 Sakai, K.; Fukushi, S.; Mizutani, T.; et al. Loop-mediated isothermal
 454 amplification-based diagnostic assay for monkeypox virus infections. *J Med Virol*455 2009, 81 (6), 1102-1108.
- 456 (28) Ryabinin, V. A.; Shundrin, L. A.; Kostina, E. B.; Laassri, M.; Chizhikov, V.;

	457	Shchelkunov,	S . 1	N.; C	'humakov,	K.;	Sin	yakov,	Α.	N.	Microarray	assay	for	detection
--	-----	--------------	--------------	-------	-----------	-----	-----	--------	----	----	------------	-------	-----	-----------

- 458 and discrimination of Orthopoxvirus species. *J Med Virol* **2006**, 78 (10), 1325-1340.
- 459 (29) Kostina, E. V.; Sinyakov, A. N.; Ryabinin, V. A. A many probes-one spot
- 460 hybridization oligonucleotide microarray. Anal Bioanal Chem 2018, 410 (23),
- 461 5817-5823.

465

- 462 (30) Altindis, M.; Puca, E.; Shapo, L. Diagnosis of monkeypox virus An overview.
- 463 *Travel Med Infect Dis* **2022**, *50*, 102459.
- 464 (31) Edghill-Smith, Y.; Golding, H.; Manischewitz, J.; King, L. R.; Scott, D.; Bray, M.;

Nalca, A.; Hooper, J. W.; Whitehouse, C. A.; Schmitz, J. E.; et al. Smallpox

- 466 vaccine-induced antibodies are necessary and sufficient for protection against
 467 monkeypox virus. *Nat Med* 2005, *11* (7), 740-747.
- 468 (32) Berthet, N.; Dickinson, P.; Filliol, I.; Reinhardt, A. K.; Batejat, C.; Vallaeys, T.;
- 469 Kong, K. A.; Davies, C.; Lee, W.; Zhang, S.; et al. Massively parallel pathogen
- 470 identification using high-density microarrays. *Microb Biotechnol* **2008**, *1* (1), 79-86.
- 471 (33) Li, S. Y.; Cheng, Q. X.; Wang, J. M.; Li, X. Y.; Zhang, Z. L.; Gao, S.; Cao, R. B.;
- 472 Zhao, G. P.; Wang, J. CRISPR-Cas12a-assisted nucleic acid detection. Cell Discov
- **2019**, *5* (1), 1.
- 474 (34) Xiong, Y.; Zhang, J.; Yang, Z.; Mou, Q.; Ma, Y.; Xiong, Y.; Lu, Y. Functional
- 475 DNA Regulated CRISPR-Cas12a Sensors for Point-of-Care Diagnostics of
- 476 Non-Nucleic-Acid Targets. *J Am Chem Soc* **2020**, *142* (1), 207-213.
- 477 (35) Xie, S.; Qin, C.; Zhao, F.; Shang, Z.; Wang, P.; Sohail, M.; Zhang, X.; Li, B. A
- 478 DNA-Cu nanocluster and exonuclease I integrated label-free reporting system for

- 479 CRISPR/Cas12a-based SARS-CoV-2 detection with minimized background signals. J
- 480 *Mater Chem B* **2022**, *10* (32), 6107-6117.
- 481 (36) Xie, S.; Tao, D.; Fu, Y.; Xu, B.; Tang, Y.; Steinaa, L.; Hemmink, J. D.; Pan, W.;
- 482 Huang, X.; Nie, X.; et al. Rapid Visual CRISPR Assay: A Naked-Eye Colorimetric
- 483 Detection Method for Nucleic Acids Based on CRISPR/Cas12a and a Convolutional
- 484 Neural Network. *Acs Synth Biol* **2022**, *11* (1), 383-396.
- 485 (37) Pang, Y.; Li, Q.; Wang, C.; Zhen, S.; Sun, Z.; Xiao, R. CRISPR-cas12a mediated
- 486 SERS lateral flow assay for amplification-free detection of double-stranded DNA and
- 487 single-base mutation. *Chem Eng J* **2022**, *429*, 132109.
- 488 (38) Chen, J. S.; Ma, E.; Harrington, L. B.; Da Costa, M.; Tian, X.; Palefsky, J. M.;
- 489 Doudna, J. A. CRISPR-Cas12a target binding unleashes indiscriminate
 490 single-stranded DNase activity. *Science* 2018, *360* (6387), 436-439.
- 491 (39) Liang, M.; Li, Z.; Wang, W.; Liu, J.; Liu, L.; Zhu, G.; Karthik, L.; Wang, M.;
- 492 Wang, K. F.; Wang, Z.; et al. A CRISPR-Cas12a-derived biosensing platform for the
- 493 highly sensitive detection of diverse small molecules. *Nat Commun* 2019, *10* (1),
 494 3672.
- 495 (40) Sui, Y.; Xu, Q.; Liu, M.; Zuo, K.; Liu, X.; Liu, J. CRISPR-Cas12a-based
- 496 detection of monkeypox virus. *J Infect* **2022**. DOI: 10.1016/j.jinf.2022.08.043.
- 497 (41) Kim, J. W.; Lee, M.; Shin, H.; Choi, C. H.; Choi, M. M.; Kim, J. W.; Yi, H.; Yoo,
- 498 C. K.; Rhie, G. E. Isolation and identification of monkeypox virus
- 499 MPXV-ROK-P1-2022 from the first case in the Republic of Korea. Osong Public
- 500 *Health Res Perspect* **2022**, *13* (4), 308-311.

- 501 (42) Gong, Q.; Wang, C.; Chuai, X.; Chiu, S. Monkeypox virus: a re-emergent threat
- 502 to humans. *Virol Sin* **2022**, *37* (4), 477-482.
- 503 (43) Feng, J.; Xue, G.; Cui, X.; Du, B.; Feng, Y.; Cui, J.; Zhao, H.; Gan, L.; Fan, Z.;
- 504 Fu, T.; et al. Development of a Loop-Mediated Isothermal Amplification Method for
- 505 Rapid and Visual Detection of Monkeypox Virus. *Microbiol Spectr* **2022**, e0271422.
- 506 (44) Zhang, Y.; Li, Q.; Guo, J.; Li, D.; Wang, L.; Wang, X.; Xing, G.; Deng, R.; Zhang,
- 507 G. An Isothermal Molecular Point of Care Testing for African Swine Fever Virus
- 508 Using Recombinase-Aided Amplification and Lateral Flow Assay Without the Need
- to Extract Nucleic Acids in Blood. *Front Cell Infect Microbiol* **2021**, *11*, 633763.
- 510 (45) Ma, Q. N.; Wang, M.; Zheng, L. B.; Lin, Z. Q.; Ehsan, M.; Xiao, X. X.; Zhu, X.
- 511 Q. RAA-Cas12a-Tg: A Nucleic Acid Detection System for Toxoplasma gondii Based
- 512 on CRISPR-Cas12a Combined with Recombinase-Aided Amplification (RAA).
- 513 *Microorganisms* **2021**, *9* (8), 1644.
- 514 (46) Zhang, A.; Sun, B.; Zhang, J.; Cheng, C.; Zhou, J.; Niu, F.; Luo, Z.; Yu, L.; Yu,
- 515 C.; Dai, Y.; et al. CRISPR/Cas12a Coupled With Recombinase Polymerase
- 516 Amplification for Sensitive and Specific Detection of Aphelenchoides besseyi. Front
- 517 Bioeng Biotechnol **2022**, *10*, 912959.
- 518 (47) Li, F.; Ye, Q.; Chen, M.; Zhou, B.; Zhang, J.; Pang, R.; Xue, L.; Wang, J.; Zeng,
- 519 H.; Wu, S.; et al. An ultrasensitive CRISPR/Cas12a based electrochemical biosensor
- for Listeria monocytogenes detection. *Biosens Bioelectron* **2021**, *179*, 113073.
- 521 (48) Li, F.; Ye, Q.; Chen, M.; Xiang, X.; Zhang, J.; Pang, R.; Xue, L.; Wang, J.; Gu,
- 522 Q.; Lei, T.; et al. Cas12aFDet: A CRISPR/Cas12a-based fluorescence platform for

- sensitive and specific detection of Listeria monocytogenes serotype 4c. Anal Chim
- 524 *Acta* **2021**, *1151*, 338248.
- 525 (49) Zhi, S.; Shen, J.; Li, X.; Jiang, Y.; Xue, J.; Fang, T.; Xu, J.; Wang, X.; Cao, Y.;
- 526 Yang, D.; et al. Development of Recombinase-Aided Amplification (RAA)-Exo-Probe
- 527 and RAA-CRISPR/Cas12a Assays for Rapid Detection of Campylobacter jejuni in
- 528 Food Samples. J Agric Food Chem 2022, 70 (30), 9557-9566.
- 529 (50) Kulesh, D. A.; Loveless, B. M.; Norwood, D.; Garrison, J.; Whitehouse, C. A.;
- 530 Hartmann, C.; Mucker, E.; Miller, D.; Wasieloski, L. P., Jr.; Huggins, J.; et al.
- 531 Monkeypox virus detection in rodents using real-time 3'-minor groove binder TaqMan
- assays on the Roche LightCycler. *Lab Invest* **2004**, *84* (9), 1200-1208.

534 For TOC only



535